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OABSTRACT
Background: Cryopyrin-associated periodic syn-
dromes (CAPS) are rare, inherited autoinflammatory
disorders associated with considerable hardship to pa-
tients. The interleukin-1 inhibitor rilonacept has been
shown to be well-tolerated and effective in preventing
CAPS symptoms in 2 pivotal studies.
Objective: In this study, the long-term effects of
rilonacept for improvement in CAPS symptoms and its
safety and tolerability were evaluated during extended
treatment.
Methods: Patients with CAPS entered a 72-week
open-label extension (OLE) following 2 sequential pla-
cebo-controlled Phase III studies (n  44), or entered
directly into the OLE (n 57). Adults received weekly
subcutaneous rilonacept 160 mg, and pediatric pa-
tients received subcutaneous rilonacept 2.2 mg/kg, up
to 160 mg/week. Safety was evaluated in all patients,
and efficacy was evaluated using a validated composite
key symptom score in 56 patients.
Results: After rilonacept treatment for 72 to 96
weeks mean key symptom score at OLE Week 72 was
reduced from 2.6 to 0, and the mean number of mul-
tisymptom flare days was reduced from 7.3 (34.8% of
days) at baseline to 0.6 (2.9% of days) at end point.
Elevated levels of inflammatory markers (eg, high sen-
sitivity-C reactive protein and serum amyloid A, were
normalized. Adverse events were generally mild to
moderate, the most common being injection site reac-
tions and upper respiratory tract infections. The inci-
dence of these events was similar to or lower than the
rate reported in the pivotal studies.
October 2012Conclusions: Long-term treatment with rilonacept
of up to 96 weeks resulted in improvements in clin-
ical signs and symptoms of CAPS and normalized
biomarkers of inflammation. Rilonacept exhibited a
generally favorable safety and tolerability profile in
adult and pediatric patients with CAPS throughout
the extended treatment period. ClinicalTrials.gov
identifier: NCT 00288704. (Clin Ther. 2012;34:
2091–2103) © 2012 Elsevier HS Journals, Inc.
Key words: cryopyrin-associated periodic syndromes,
interleukin-1, long-term, rilonacept.
INTRODUCTION
Cryopyrin-associated periodic syndromes (CAPS) are a
group of rare, inherited autoinflammatory disorders
encompassing familial cold autoinflammatory syn-
drome (FCAS) (known also as familial cold urticaria),
Muckle-Wells syndrome (MWS), and neonatal-onset
multisystem inflammatory disease (NOMID) (known
also as chronic infantile neurologic cutaneous articular
syndrome). These disorders are usually inherited in an
autosomal dominant fashion, and are typically, but not
always, associated with mutations in theNLRP3 gene,
which codes for the protein cryopyrin.1–3 Disease-as-
ociated NLRP3 gene mutations result in dysregula-
tion of the cryopyrin inflammasome, generating inap-
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Clinical Therapeuticspropriately high levels of the proinflammatory
cytokine interleukin (IL)-1, resulting in the multisys-
em inflammatory manifestations of CAPS.4
Although they vary in severity and phenotype,
FCAS, MWS, and NOMID can impair daily activities
in affected patients. Although patients with NOMID
have a more chronic and severe pattern of symptoms,
patients with FCAS and MWS experience frequent, in-
termittent episodes of incapacitation, which may last
from hours to days.5,6 Symptoms of FCAS and MWS
uch as fever, rash, arthralgia, fatigue, and conjuncti-
itis wax and wane and severity varies from day to
ay.5 Patients focus on limiting exposure to triggers
(such as cool temperatures in patients with FCAS) to
minimize flares, which interferes with their ability to
lead productive lives and participate in normal family,
social, and work activities.7–9
Patients with CAPS generally have chronically el-
evated levels of acute-phase proteins, most notably
serum amyloid A (SAA) and C-reactive protein
(CRP).7,10 Elevated SAA levels are associated with
reactive amyloidosis and renal failure, a serious
complication of CAPS and other hereditary autoin-
flammatory disorders.5,7,10,11 Reactive amyloidosis
s present in2% of patients with FCAS, and25%
n those with MWS, reflecting the especially intense
nd prolonged acute-phase response that is charac-
eristic of these syndromes.5,7,10,11
CAPS is not well recognized among physicians or
patients because only a few hundred cases have been
identified in the United States.11Many patients are pre-
cribed, or self-medicate with, corticosteroids, non-
teroidal anti-inflammatory drugs, or antihistamines,
hich generally do not adequately relieve symp-
oms.1,5,11 Although high-dose corticosteroids provide
improvements in some symptoms in FCAS and MWS,
side effects preclude long-term use.11
Rilonacept is a soluble decoy receptor fusion pro-
tein that binds IL-1 and IL-1, thus preventing their
activation of cell surface receptors. Rilonacept was
generated using so-called trap technology and is thus
also known as the IL-1 Trap.12 In the United States and
European Union, rilonacept has been approved for the
treatment of CAPS.13,14 In an open-label pilot study
nvolving 5 patients with FCAS, rilonacept was shown
o improve symptoms and reduce elevated levels of
oth CRP and SAA.10 The results of 2 pivotal, sequen-
ial, placebo-controlled, Phase III studies have shown
hat subcutaneous rilonacept 160 mg weekly provides
2092arked and lasting improvement in the clinical signs
nd symptoms associated with CAPS, with a generally
avorable safety and tolerability profile.1 Treatment of
atients with FCAS or MWS with rilonacept resulted
n a significant (84%) improvement in a composite
ymptom score and normalized elevated SAA and
s-CRP levels. Unlike previous studies of therapies for
APS, these 2 studies were multicenter, large (n  47)
elative to the total population of patients with CAPS
n North America, and used a validated instrument for
APS symptom self-assessment to demonstrate the ef-
cacy of rilonacept in adults.1
Because CAPS is a lifelong disorder, it is important
to evaluate the effects of long-term treatment on effi-
cacy and safety. Therefore, a long-term follow-up
study of open-label rilonacept treatment was under-
taken, initially among participants who were enrolled
in the 2 pivotal randomized studies, but subsequently
including other CAPS patients who were eligible for
rilonacept therapy. The primary objective of our study
was to assess the effect of rilonacept on the clinical
signs and symptoms of CAPS during an extended pe-
riod of treatment. Secondary objectives were to deter-
mine the safety and tolerability of rilonacept in patients
with CAPS, and to assess the effect of rilonacept on
laboratory measures of inflammation. This report in-
cludes the efficacy and safety findings from this open-
label, long-term follow-up evaluation.
METHODS
The protocol for the open-label study was reviewed
and approved by the institutional review board for
each participating site and conducted in accordance
with the ethical principles of the Declaration of Hel-
sinki, consistent with good clinical practice and ap-
plicable regulatory requirements. All adult patients
provided written informed consent before participa-
tion in the open-label phase. For a pediatric patient
to participate, an adult parent or guardian was re-
quired to provide written informed consent, with the
additional requirement that a child aged 7 to 11
years sign a separate assent document, and a child
aged12 years provide assent on the main Informed
Consent Form.
Study Design
This was a prospectively planned long-term (72-
week), open-label, extension study of the efficacy,
safety, and tolerability of rilonacept in patients with
Volume 34 Number 10
p
l
w
s
t
y
F
b
F
o
i
t
p
h
a
t
e
t
s
r
t
d
a
c
c
M
H.M. Hoffman et al.NLRP3 mutation-positive CAPS (FCAS or MWS),
conducted at 30 centers in the United States. Eligible
patients included those who had completed 2 prior
sequential Phase III studies,1 as well as new CAPS pa-
tients who had not previously participated in a study of
rilonacept (Figure 1). The prior Phase III studies con-
sisted of Study 1, which incorporated a 3-week screen-
ing period followed by a 6-week, randomized (1:1),
double-blind, placebo-controlled treatment period for
evaluating subcutaneous injections of rilonacept 160
mg weekly relative to placebo in adult patients with
FCAS or MWS. Patients who completed Study 1 im-
mediately entered into Study 2, which had 2 parts: the
first part consisted of 9 weeks of weekly single-blind
treatment with subcutaneous rilonacept 160 mg, and
the second part consisted of a 9-week double-blind
randomized (1:1) withdrawal with weekly injections of
rilonacept 160 mg or placebo.1 Patients who com-
leted Study 2 were then eligible to enroll in the open-
abel study. In addition, the new CAPS patients who
ere allowed to enroll directly into the open-label
tudy did so under 2 amendments to the original pro-
ocol and included mutation-positive adult (age >18
ears) and pediatric (age 7–17 years) patients with
6-wk 
Double-
Blind
Phase
9-wk
Single-
Blind
Phase
9-wk
Randomized
Withdrawal
or or
Placebo Placebo
Screening Period
for new patients
Wk
1
Wk
6
Wk
15
Wk
24
3-wk
Screening
Period 
Rilonacept
160
mg/wk 
Rilonacept
160
mg/wk 
Rilonacept
160
mg/wk 
Figure 1. Design of the prospectively planned long-te
safety, and tolerability of rilonacept in pat
periodic syndromes (familial cold autoinflaCAS or MWS. The 2 amendments were used as the r
October 2012asis for 2 additional patient cohorts as shown in
igure 1 and described below.
Patients who had completed Study 2 enrolled in the
pen-label phase and were seen in the clinic at 6-week
ntervals for routine and disease-specific laboratory
esting.1New patients who enrolled into the open-label
hase under the first protocol amendment (Cohort 1)
ad a 3-week screening period during which patients
ssessed and recorded their daily disease symptoms ac-
ivity; these patients then returned to the clinic at least
very 6 weeks for routine and disease-specific labora-
ory testing. The second protocol amendment was de-
igned principally to allow evaluation of the safety of
ilonacept in the largest possible number of CAPS pa-
ients. Those who enrolled in the open-label phase un-
er this amendment, Cohort 2, entered the study with
n abbreviated 3-week screening phase, without re-
ording of daily disease activity.
Patients
Patients who met the inclusion criteria, including
genetic evidence of a NLRP3 mutation, and exhibited
lassic signs and symptoms of CAPS (FCAS and/or
WS) could be enrolled. Patients who enrolled di-
72-wk Open-Label Extension
Wk
48
Wk
96
Rilonacept:
Adults: 160 mg/wk
Adolescents: 2.2 mg/kg/wk (max. 160 mg)
2-week), open-label, extension study of the efficacy,
with NLRP3 mutation-positive cryopryin-associated
tory syndrome/Muckle-Wells syndrome).rm (7
ients
mmaectly in the open-label phase who were taking anak-
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Clinical Therapeuticsinra (an IL-1 receptor antagonist) were required to stop
taking it following the informed consent procedure at
the screening visit. Key reasons for exclusion included
recent treatment with a live (attenuated) virus vaccine;
recent treatment (5 half-lives) with a tumor-necrosis
factor inhibitor or investigational agent; concurrent
treatment with anakinra; any other active systemic in-
flammatory condition; standard infectious disease ex-
clusions, including listeriosis, HIV, and hepatitis B or C.
In addition, active tuberculosis, a history of tuberculo-
sis (positive tuberculin purified protein derivative test),
or a chest radiograph consistent with prior tuberculo-
sis was cause for exclusion.
Treatment
All adult patients received rilonacept 160 mg/wk
during open-label treatment, and children received 2.2
mg/kg/wk up to a maximum of 160 mg. Administra-
tion was by subcutaneous injection. The first injection
of medication was administered by clinic staff and the
second injection was administered by patients or their
caregivers as part of the training process for weekly
self-administration. All subsequent doses were self-
administered or given by family members or health
care practitioners. Each patient or the parent/guard-
ian was instructed to store the sealed, sterile, single-
use vials in their home refrigerator and trained to
reconstitute the drug with 2.3 mL sterile water just
before injection. Patients were also instructed to re-
cord all administrations in drug diaries, noting the
date and location of each injection, the dates of any
missed doses, and any injection-site reactions. Used
and unused vials were returned at study visits, and
compliance evaluated based on patient diaries and
returned vials.
Study Assessments
Disease activity was evaluated during the open-label
phase with a daily health assessment form (DHAF), a
1-page, self-administered questionnaire that has been
validated for evaluating symptom severity in adult pa-
tients with CAPS.15 For 3weeks before each clinic visit,
atients (or parents/guardians, as appropriate) were
sked to complete a DHAF each evening, rating the
everity of key symptoms (eg, rash, feeling of fever/
hills, joint pain, eye redness/pain, and fatigue), during
he previous 24 hours. In the case of parents/guardians,
he same individual was encouraged to provide the
valuation data. Ratings were provided via linear rat- y
2094ng scales in which circles were marked from 0 (no
everity) to 10 (very severe) in half-step units. A daily
ey symptom score (KSS) was derived by adding the
aily score for each key symptom and dividing by 5
number of key symptoms), and a mean KSS for each
1-day assessment period was derived by adding the
ean daily KSS and dividing by 21 (number of days in
he observation period). Patients also completed a pa-
ient’s global assessment of disease activity form
“Considering all the ways that FCAS or MWS affects
ou, how are you doing. . .?” 0  very well to 10 
ery poor), and an assessment of limitation of daily
ctivities form (“Did you limit your activities today. . . .?”
 no limitation to 10  much limitation). Mean
hanges from baseline in the number of multisymptom
are days (ie, number of days during a 21-day period
hen the daily KSS was3 for 2 or more of the symp-
oms) and single-symptom flare days (ie, number of
ays in a 21-day period when the daily KSS was3 for
t least 1 key symptom) were also measured. Standard
entral laboratory testing was used to measure levels of
AA (laboratory reference range 0.7–6.4 mg/L) and
igh-sensitivity CRP (laboratory reference range 
.0–8.4 mg/L), which were assessed at visits up to and
ncluding Week 24 of open-label treatment.
The primary efficacy end point in this trial was the
ean change from the predose screening evaluation
eriod to the end point evaluation period (ie, the 21
ays before theWeek 72 visit) in the mean KSS derived
rom the DHAF. For patients enrolled after complet-
ng the second of the 2 prior sequential Phase III
tudies, the screening period was the 21 days imme-
iately before the day of the first dose of double-
lind study medication in Study 1. For patients in
ohort 1 who enrolled directly into the open-label
rial, this period consisted of the initial 3-week
creening period during which daily disease activity
as reported; patients from Cohort 2 did not report
aily disease activity during their screening period
nd thus the primary efficacy end point was not
valuable in these patients.
Adverse events (AEs) and vital signs were recorded,
longwith physical examinations, screening tuberculin
kin tests, screening chest radiographs, electrocardio-
rams, clinical laboratory tests (PPD Global Central
aboratories, HighlandHeights, Kentucky), and deter-
ination of plasma rilonacept and serum antirilona-
ept antibody levels, using highly sensitive ELISA anal-
ses.16 Patients reported any injection site reactions on
Volume 34 Number 10
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H.M. Hoffman et al.the diary form. Standard analyses of safety were per-
formed on AEs, clinical laboratory results, vital signs,
and electrocardiograms. Serious AEs were defined ac-
cording to the International Conference on Harmoni-
sation E2 guidelines17; all AEs were coded using
edDRA* version 11.0.
Analysis
Data were summarized using descriptive statistics
for the entire cohort (adults and children). Last ob-
servation carried forward was used to imputate
missing data due to patient withdrawal. All safety
analyses were undertaken on the full analysis set,
which included all enrolled patients who were
known to be genotype positive for CAPS and who
received at least 1 dose of study medication. For the
primary efficacy analysis (mean KSS), all patients
enrolling from the Phase III studies and the Cohort 1
patients who enrolled directly into the open-label
treatment phase were included (Cohort 2 patients
were not evaluable for the primary end point). For
secondary analyses not dependent on DHAF data
(physician global assessment and serum biomark-
ers), all patients receiving open-label treatment were
included.
RESULTS
Of 47 patients who enrolled in the 24-week, multi-
phase, sequential, Phase III pivotal trials of rilonacept,
44 entered into the open-label treatment phase in 22
centers in the United States. Fifty-seven new patients
(12 in Cohort 1 and 45 in Cohort 2 [49 adults and 8
adolescents]) also enrolled directly into open-label
treatment. A total of 101 patients received study med-
ication, and had evaluable safety data for 72 weeks of
open-label treatment (up to 96weeks of treatment with
rilonacept if including the initial 24-weeks of the
prior Phase III trials) (Figure 2). Two patients died
during the study (1 from coronary artery occlusion
and 1 from streptococcal meningitis); neither of the
2 deaths was considered by the investigator to be
related to treatment. A further 18 patients withdrew
from open-label treatment for decision by the spon-
sor (n  15), adverse event (n  1), request by pa-
tient (n  1), and other (n  1). Approximately two
hirds of patients (66.3%) were women; the mean
ge was 43.6 years. All were white and NLRP3 gene
utation-positive, and the average baseline weight
as 77 kg. The average age of patients enrolled di-
October 2012ectly into the open-label treatment (Cohorts 1 and
) was lower than the age of those who had partici-
ated in the Phase III trials largely due to the enroll-
ent of 8 pediatric patients, ages 12 to 17 years,
etween the 2 cohorts. Baseline characteristics of
atients are shown in Table I. Eighty-seven patients
86%) took all scheduled weekly subcutaneous self-
njections during the open-label phase.
Efficacy
The mean baseline KSS was 2.8 for the initial group
of 44 patients, and the mean end point KSS at open-
label study Week 72 (after treatment with rilonacept
for 72 to 96 weeks) was 0.4, showing a marked im-
provement (mean change  –2.4) (Table II); the mean
end point KSS and themagnitude of the reduction from
baseline in KSS at Week 72 (mean KSS  0.4; mean
hange from baseline  –2.4) were similar to those
bserved with rilonacept at the end of the placebo-
ontrolled portion of Study 1 (Week 6: mean KSS 
.5; mean change from baseline  –2.6).1 Cohort 1
patients enrolling directly into the open-label phase
had amean baseline KSS of 2.1, which decreased to 0.1
at Week 72 (Table II). When both patient groups were
considered together, the mean reduction from baseline
in KSS was –2.3.
Both groups of patients also showed reductions in
the number of multisymptom flare days from base-
line to Week 72 (Table II), and in the number of
single-symptom flare days from baseline to Week 72
(Table II). The magnitude of these reductions was
similar to the reductions observed at Week 6 of the
initial double-blind study.1
A marked improvement from baseline to Week 72
in both groups also was observed when evaluating
the maximum score for any single symptom (Figure
3). An analysis of individual symptom scores re-
vealed that baseline scores of 1.2 to 3.7 were reduced
by 1.0 to 3.2 at the Week 72 end point (Figure 4). An
improvement in mean patient’s global assessment
scores from 3.4 at baseline to 0.4 at Week 72 was
observed in the combined analysis of Phase III pa-
*MedDRA®, the Medical Dictionary for Regulatory Activities
terminology, is the international medical terminology devel-
oped under the auspices of the International Conference on
Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). MedDRA® trademark
is owned by IFPMA on behalf of ICH.
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Clinical Therapeuticstients and Cohort 1 patients (Table II). The patient
assessment of limitation of daily activities showed an
improvement from baseline to the Week-72 end
point for the 44 patients from the Phase III studies
(mean change  –2.4); the change in this score for
ohort 1 patients entering directly into open-label
reatment was –1.9 (Table II).
Physician’s global assessment scores were assessed
n all patients entering from the Phase III studies, and
ohort 1 and 2 entering directly into open-label treat-
ent, and serum biomarker levels were assessed in
ost (n  86). All 3 groups showed marked improve-
ent in physician’s global assessment scores from
aseline to Week 24 of open-label therapy (Table III).
imilarly, all 3 groups of patients had reductions in
s-CRP and SAA levels from baseline to Week 24, to
Patients Partic
n
Original cohort 
n = 44 
Patients Who Participated in 
phase 3 studies* 
Cohort 1
n = 12
Patients who enr
open-label treatm
disease symptom
n = 44
Received at least one dose*  
n = 12
Received at least
n = 2
Prematurely Withdrawn During
the Study  
n = 0
Prematurely Wi
the Study* 
Other: 1
Death: 1† pneumococcal 
meningitis after last dose
Figure 2. Distribution of patients with NLRP3 mut
(familial cold autoinflammatory syndrom
label extension [N  101]). *Ten of 44 p
open-label phase, and were treated cont
curred during treatment with rilonacept
medication..0 mg/L and 9.6mg/L, respectively, including normal- t
2096zation of mean hs-CRP values (6.4 mg/L), and mean
AA values that were at or approached normal (Table
II). Baseline hs-CRP and SAA levels were greater in pa-
ients entering from the Phase III studies than in Cohort 1
r 2 patients, and consequently the magnitude of the re-
uction in these parameters was greater in the Phase III
atient cohort.
Tolerability
Rilonacept was generally well tolerated during the
overall 96-week treatment period that included the ini-
tial double-blind studies1 and the 72-week open-label
xtension. The most commonly reported AEs in all
atients were injection site reactions and upper respi-
atory tract infections (Table IV). The adverse event
rofile of rilonacept in pediatric patients was similar to
g in the OLE,
irectly into
ith pre-dose
ments     
Cohort 2
n = 45
Patients who enrolled directly into
open-label treatment without pre-
dose disease symptom assessments  
se  
n = 45
Received at least one dose 
n During
n = 18
Prematurely Withdrawn During the
Study*   
Adverse event: 1
Patient request: 1
Death: 1† atherosclerosis after
treatment 
Decision by the Sponsor: 15
-positive cryopryin-associated periodic syndromes
uckle-Wells syndrome participating in the open-
ts participated in Studies 1 and 2 as well as in the
sly with rilonacept for 96 weeks; †One death oc-
1 occurred 53 days after the last dose of studyipatin
 = 101 
olled d
ent w
 assess
 one do
thdraw
ation
e/M
atien
inuou
andhat in adult patients; the most commonly reported AE
Volume 34 Number 10
H.M. Hoffman et al.among pediatric patients was injection site reaction.
Adverse events reported during open-label treatment
were generally mild to moderate in severity. Two se-
vere AEs were recorded during this phase; 1 patient
from the Phase III studies developed pneumococcal
meningitis with headache, rash, pruritus, hypokale-
mia, hyponatremia, and nephrolithiasis, and 1 patient
entering directly into open-label treatment developed a
tooth abscess and joint swelling.
Nine serious AEs were recorded in 7 patients, and
all were considered by the investigator to be unrelated
to the study medication. These serious AEs included 2
patients who died during the study; a 71-year-old fe-
male patient with a prior history of recurrent skin in-
fections died after developing sinusitis and pneumo-
coccal meningitis, and a 37-year-old patient died
suddenly due to coronary atherosclerosis with obesity
listed as a contributing factor. This death occurred 53
days after the last confirmed dose of study drug and
autopsy results included proximal occlusion of the left
Table I. Demographic and baseline characteristics o
ated periodic syndromes (familial cold auto
[MWS]) in the open-label extension (OLE) t
Enrolled from the
Pivotal Trials
(n  44)
Age, y
Mean (SD) 51.3 (16.3)
Range 23–79
Gender (male:female) 14:30
Mean (SD) screening key
symptom score 2.80 (1.72)
Diagnosis, n
FCAS 41
MWS 3
FCAS/MWS 0
CIAS1 gene mutation, n (%) 44 (100)
Ethnicity, n (%)
White, non-Hispanic 44 (100)
Mean height, cm (SD) 168.2 (7.8)
Mean weight, kg (SD) 74.7 (16.2)
*Patients enrolled in Cohort 2 did not complete the screenianterior descending coronary artery, with histologic
October 2012examination showing focal interstitial fibrosis of heart
tissue and early intra-alveolar acute inflammatory cell
infiltrates of lung tissue. The hs-CRP values for this
patient were 47.6 mg/dL, 2.2 mg/dL, 1.9 mg/dL, and
1.4 mg/dL at Open-Label Day 1, Week 6, Week 12,
and Week 24, respectively. In the other death, no au-
topsy was performed, and although the investigator
judged the severity of the infectious event severe, it was
also deemed by the investigator as not related to rilona-
cept treatment.
Other serious AEs were sciatica and arthritis (n  1),
gastroesophageal reflux disease (n  1), cholelithiasis
(n 1), and renal colic (n 1). One patient withdrew
from open-label treatment because of pulmonary em-
bolism, hypokalemia, and hyponatremia, all of which
were considered serious AEs.
Mean changes in vital signs (systolic and diastolic
blood pressure, sitting pulse, temperature, and respira-
tion rate) from baseline to the open-label extension
were not clinically significant, and most clinical labo-
ents with NLRP3 mutation-positive cryopryin-associ-
matory syndrome [FCAS]/Muckle-Wells syndrome
f treatment with rilonacept.
led Directly
E Cohort 1
 12)
Enrolled Directly
in OLE Cohort 2
(n  45)
All
Treated Patients
(n  101)
.4 (15.6) 40.4 (16.8) 43.6 (18.1)
13–56 12–80 12–80
4:8 16:29 34:67
07 (0.98) NA* 2.64 (1.61)
11 43 95
0 0 3
1 2 3
12 (100) 45 (100) 101 (100)
12 (100) 45 (100) 101 (100)
.8 (8.1) 168.7 (7.0) 168.3 (7.5)
.4 (16.6) 82.1 (16.8) 77.0 (18.1)
ly health assessment form questionnaire.f pati
inflam
rial o
Enrol
in OL
(n
27
2.
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66
ng dairatory measures showed minor fluctuations in mean
2097
Ta
bl
e
II.
Su
m
m
ar
y
of
m
ea
n
(S
D
)
va
lu
es
fo
r
ef
fic
ac
y
pa
ra
m
et
er
s
at
ba
se
lin
e
an
d
en
d
po
in
t.
En
te
rin
g
fr
om
Ph
as
e
III
Tr
ia
ls
(n

44
)
C
oh
or
t
1
En
te
rin
g
O
pe
n-
La
be
l
Ph
as
e
(n

12
)
C
om
bi
ne
d
A
va
ila
bl
e
D
at
a
(n

56
)
B
as
el
in
e
En
d
of
St
ud
y
1
(W
ee
k
6)
W
ee
k
72
of
O
LE
B
as
el
in
e
W
ee
k
72
of
O
LE
B
as
el
in
e
W
ee
k
72
of
O
LE
C
ha
ng
e
fr
om
B
as
el
in
e
K
SS
*
2.
8
(1
.7
)
0.
5
0.
4
(0
.6
)
2.
1
(1
.0
)
0.
1
(0
.2
)
2.
6
(1
.6
)
0.
4
(0
.5
)

2.
4
M
ul
tip
le
sy
m
pt
om
fla
re
da
ys
†
7.
6
(6
.7
)
0.
1
0.
8
(3
.4
)
5.
9
(5
.1
)
0.
0
(0
.0
)
7.
3
(6
.4
)
0.
6
(3
.0
)

6.
7
36
.2
%
3.
8%
28
.1
%
34
.8
%
2.
9%
Si
ng
le
sy
m
pt
om
fla
re
da
ys
‡
12
.8
(6
.7
)
1.
1
1.
8
(4
.9
)
12
.5
(6
.3
)
0.
4
(1
.4
)
12
.7
(6
.6
)
1.
5
(4
.4
)

11
.0
61
.0
%
8.
6%
59
.5
%
1.
9%
60
.5
%
7.
1%
Pa
tie
nt
’s
gl
ob
al
as
se
ss
m
en
t
sc
or
e§
3.
4
(2
.1
)
0.
9
0.
5
(0
.7
)
3.
2
(1
.5
)
0.
3
(0
.4
)
3.
4
(1
.9
)
0.
4
(0
.6
)

3.
0
Li
m
ita
tio
n
of
da
ily
ac
tiv
iti
es

2.
7
(2
.3
)
0.
8
0.
3
(0
.5
)
2.
4
(2
.0
)
0.
5
(1
.2
)
2.
6
(2
.3
)
0.
3
(0
.7
)

2.
3
K
SS

K
ey
sy
m
pt
om
sc
al
e;
O
LE

O
pe
n-
la
be
le
xt
en
si
on
.
*S
ca
le
is
0

no
ne
to
10

ve
ry
se
ve
re
.
†
D
ay
in
w
hi
ch
at
le
as
t
2
sy
m
pt
om
s
sc
or
e

3.
‡
D
ay
in
w
hi
ch
at
le
as
t
1
sy
m
pt
om
sc
or
es

3.
§
Sc
al
e
is
0

do
in
g
ve
ry
w
el
lt
o
10

do
in
g
ve
ry
po
or
.
 S
ca
le
is
0

no
lim
ita
tio
n
to
10

m
uc
h
lim
ita
tio
n.
Clinical Therapeuticschange from baseline. Both systolic (3.3 mm Hg) and
diastolic (1.7 mm Hg) blood pressure increased
slightly, and pulse rate (–4 bpm) decreased slightly
over the course of open-label treatment. Body weight
increased by a mean of 2.9 kg. Small mean reductions
in white blood cell, neutrophils, and platelet counts
compared with baseline were reported with rilonacept
treatment, but mean levels remained within the normal
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Figure 3. Mean (SD) maximum score for any single
symptom in patients withNLRP3mutation-
positive cryopryin-associated periodic syn-
dromes(familialcoldautoinflammatorysyn-
drome/Muckle-Wells syndrome) at baseline
and Week 72 of the open-label phase of
treatment with rilonacept.
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Figure 4. Mean individual symptoms scores at
baseline and Week 72 of open-label
treatment with rilonacept for all patients
with NLRP3 mutation-positive cryo-
pryin-associated periodic syndromes (fa-
milial cold autoinflammatory syndrome/
Muckle-Wells syndrome) (N  56).2098 Volume 34 Number 10
H.M. Hoffman et al.reference range. An increase in total cholesterol of 15
to 17 mg/dL observed during Weeks 6 to 56 of open-
label treatment from a mean of 176.8 mg/dL (n 101)
at baseline was accompanied by increases in fasting
lipid fractions (ie, HDL, LDL, and triglycerides), but
mean levels remained within the normal reference
range. Decreases in alkaline phosphatase levels from
the baseline mean of 67.1 mU/mL were seen at all time
points; mean decreases ranged from –7.5 to –14.3
mU/mL during open-label treatment. Across time
points, small mean increases in alanine aminotransfer-
ase (2.0–3.5 mU/mL), aspartate aminotransferase
(2.0–3.0 mU/mL), and creatine phosphokinase levels
(6.5–29.8 mU/mL) were also recorded. Two patients
were temporarily discontinued from treatment with
rilonacept due to increases in alanine aminotransferase
and aspartate aminotransferase, 1 of whom had ele-
vated levels of these enzymes at screening.
Antirilonacept antibody levels were measured
Table III. Physician’s global assessment scale score
open-label treatment with rilonacept.
Entering from
Phase III Trials
(n  44)
Mean (SD) physician’s global
assessment score
Baseline 5.1 (2.0)
Week 24 1.4 (1.9)
n  42
Mean (SD) change to Week 24 3.9 (2.3)
Mean (SD) hsCRP, mg/L*
Baseline 27.1 (15.3)
Week 24 5.6 (16.1)
n  43
Mean (SD) change to Week 24 20.9 (17.7)
Mean (SD) SAA, mg/L†
Baseline 89.6 (97.6)
Week 24 14.7 (62.2)
n  43
Mean (SD) change to Week 24 71.9 (106.7)
hsCRP  high sensitivity C-reactive protein; SAA serum a
*Laboratory reference range for normal: 0.0—8.4 mg/L.
†Laboratory reference range for normal: 0.7—6.4 mg/L.during the pivotal Phase III studies and the first 24
October 2012weeks of open-label treatment. Although antirilona-
cept-binding antibodies developed in 24% of pa-
tients administered rilonacept, the titers were gener-
ally low to moderate (800) with only 2 patients
having titers 800 (1 of 1600 and 1 of 3200). The
presence of these antibodies did not appear to have
an impact on total rilonacept levels, which were ap-
proximately 27 mg/L (mean rilonacept trough levels
at 160 mg/wk). Only 2 patients demonstrated a no-
table reduction in total rilonacept levels at Weeks 40
and 72 of the open-label period that may have been
associated with the appearance of neutralizing anti-
rilonacept antibodies. In the remaining patients, lev-
els of total rilonacept did not appear to decrease
substantially over time and were similar in most pa-
tients at Week 6 and at Week 96.
DISCUSSION
Recent elucidation of the genetic basis for CAPS and
levels of inflammatory biomarkers at Week 24 of
ort 1 from
-Label Phase
n  12)
Cohort 2 from
Open-Label Phase
(n  45)
All
Treated Patients
(n  101)
4.8 (2.4) 6.7 (2.7) 5.8 (2.5)
0.5 (0.8) 0.9 (1.5) 1.1 (1.6)
n  12 n  31 n  85
4.2 (2.2) 5.7 (3.1) 4.6 (2.7)
5.4 (10.2) 17.6 (13.6) 21.5 (14.8)
2.4 (4.1) 2.2 (3.4) 4.0 (11.7)
n  12 n  31 n  86
3.0 (7.8) 13.0 (11.6) 16.9 (15.0)
1.4 (91.7) 50.1 (51.6) 68.7 (80.9)
7.3 (16.4) 3.5 (1.7) 9.6 (44.4)
n  12 n  31 n  86
4.1 (76.7) 37.0 (43.4) 56.8 (84.9)
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Clinical Therapeuticsdevelopment of IL-1 targeted therapy for CAPS.1,7,8,10
Our trial demonstrates the long-term benefits of
weekly subcutaneous rilonacept in reducing the signs
and symptoms of CAPS and normalizing biomarkers
of inflammation. Among those patients who enrolled
in the open-label trial from the Phase III studies, the
values of all efficacy end points at the end of the 72-
week open-label period and the magnitude of the re-
duction from baseline were similar to what was ob-
served at the end of the prior 6-week double-blind
treatment.1 This similarity suggests that efficacy was
sustained for up to 96 weeks of rilonacept treatment
(72 weeks of open-label treatment following 24-week
sequential pivotal trials). These benefits included im-
provement in the primary efficacy variable (mean KSS)
that evaluated clinical signs and symptoms, as well as
improvements in the number of flare days. During 96
weeks of treatment (at Week 72 of open label treat-
ment), the changes from baseline in patient’s global
assessment score and patient’s assessment of limitation
of daily activities score were consistent with those pre-
viously observed at the end of the double-blind period.
In addition, physician’s global assessment scores sub-
Table IV. Incidence (%) of treatment-emergent adve
open-label (OL) treatment with rilonacept.
Entering
Trials
Any AE 43
Injection site reactions
Erythema 6
Pruritus 2
Bruising 6
Swelling 4
Irritation 4
Infections
Influenza 5
Sinusitis 5
Nasopharyngitis 7
Urinary tract infection 3
Bronchitis 4
Respiratory, thoracic, and mediastinal
disorders
Sinus congestion 3stantially improved and mean SAA and CRP levels f
2100showed marked reductions during 48 weeks of treat-
ment with rilonacept. All of these results support the
conclusion that rilonacept effectively reduces signs and
symptoms of CAPS during extended treatment. The
lack of response to placebo that was observed in the
pivotal placebo-controlled double-blind study (Study 1)
supports this assessment of the efficacy of rilonacept ob-
served in the setting of an open-label extension such as
that reported here.
Overall, rilonacept demonstrated a generally fa-
vorable safety and tolerability profile during 96
weeks of treatment. Relative to the blinded portions
in the initial 2 double blind studies, in which 48%
and 36% of patients, respectively, treated with
rilonacept reported injection site reactions,1 no no-
able difference was observed in the rate of injection
ite reactions reported in the subsequent 72-week
pen-label phase. The difference between the per-
ent of patients reporting injection-site reactions
uring the 72-week open-label phase for those who
ntered the extension after completing the blinded
tudy phases (9% to 14%) compared with those who
ntered directly (5% to 46%) is notable. Possibilities
vents (AEs) occurring in at least 5 subjects during
Phase III
44)
Enrolled in OL Phase
(n  57)
All Patients
(n  101)
) 47 (82.5) 90 (89.1)
) 26 (45.6) 32 (31.7)
11 (19.3) 13 (12.9)
) 6 (10.5) 12 (11.9)
7 (12.3) 11 (10.9)
3 (5.3) 7 (6.9)
) 5 (8.8) 10 (9.9)
) 5 (8.8) 10 (9.9)
) 2 (3.5) 9 (8.9)
5 (8.8) 8 (7.9)
1 (1.8) 5 (5.0)
2 (3.5) 5 (5.0)rse e
from
(n 
(97.7
(13.6
(4.5)
(13.6
(9.1)
(9.1)
(11.4
(11.4
(15.9
(6.8)
(9.1)
(6.8)or the difference in injection site reaction rates in-
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H.M. Hoffman et al.clude AE reporting fatigue in those who entered the
extension from the prior blinded phases and chance
difference due to small group numbers. Nine serious
AEs were recorded in 7 patients, including 2 that
resulted in death. All were considered by the inves-
tigator to be unrelated to the study drug.
As an inhibitor of IL-1, rilonacept has the poten-
tial to interfere with the immune response to infec-
tions, and it is prudent to discontinue treatment in
the setting of a serious infection. During the open
label extension, there was a trend toward more fre-
quent reporting of infections (predominantly upper
respiratory tract infections) by patients who entered
the extension after completing the blinded study
phases (7%–11%) compared with those who entered
directly (2%– 9%). The reporting rates in both
groups were notably lower than the 26% rate of AEs
due to infection reported by rilonacept-treated pa-
tients in the initial double-blind study.1 This may be
due to the fact that the double-blind study was con-
ducted during winter, and the data likely reflect a
more realistic picture of infection rates throughout
the calendar year. The younger mean age of the pa-
tients who directly entered the study could also po-
tentially play a role, although it is difficult to make
conclusions based on groups of this size.
Treatment with rilonacept was associated with
reductions in neutrophil and platelet counts. Such
hematologic changes have also been reported with
the other anti-IL-1 agents anakinra18 and canaki-
umab.19 It is possible that these change may repre-
ent an “acute-phase” class effect that can be hy-
othesized to result from a treatment-related
ecrease in chronic inflammation. A small to modest
ncrease in total cholesterol in CAPS patients who
eceived rilonacept may also potentially result from
treatment-related decrease in inflammation be-
ause cholesterol is reduced as part of the acute-
hase response;1,20 other anticytokine agents have
also been reported to increase cholesterol in patients
with chronic inflammatory diseases.21–24
Some patients who received rilonacept developed
detectable antirilonacept antibodies consistent with
the recognized potential for immunogenicity associ-
ated with protein therapeutics.25 However, the clinical
significance of these antibodies is uncertain, because no
evident effect was seen on the efficacy of rilonacept or
on safety parameters.
October 2012This study has a number of limitations. First, it was
an open-label study with efficacy outcomes measures
compared principally with baseline. Second, the main
efficacy outcome instrument, the DHAF, was validated
for adult patient self-assessment, but not for use by an
adult parent/guardian to assess a pediatric patient.
Third, a number of protocol amendments were under-
taken during the course of the study, such that data for
each parameter were not obtained from the entire co-
hort of patients. Fourth, compared with studies in
more common diseases, this study includes a relatively
small number of patients. However, given the rarity of
this condition, the sample size is relatively large. In
fact, approximately one third of the estimated US pop-
ulation of CAPS patients was enrolled. Therefore, not-
withstanding the limitations described above, this
study contributes substantially to the published litera-
ture on rilonacept in CAPS, not only because of its size
but also because of the long duration of treatment (up
to 96 weeks).
CONCLUSIONS
Weekly treatment with rilonacept up to 96 weeks in
patients with FCAS and MWS resulted in levels of
CAPS disease activity and improvements from baseline
that were similar to those observed after 6 weeks of
treatment. In addition, after treatment with rilonacept
for up to 48 weeks, biomarkers of inflammation dem-
onstrated normalization that was similar to that ob-
served after 6weeks of treatment. Rilonacept exhibited
a generally favorable safety and tolerability profile in
adult and pediatric patients throughout the extended
period of treatment.
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